Active Biotech's Partner Teva Initiates A Further Clinical Trial In Multiple Sclerosis

LUND, Sweden, Nov. 4, 2013 (GLOBE NEWSWIRE) --
Active  Biotech  (NASDAQ  OMX NORDIC: ACTI)announced  today  that  its  partner  Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)  will  initiate  a  further  clinical  trial,  LIBRETTO,  to  evaluate theefficacy,  safety and tolerability of two doses of oral laquinimod (0.6 and 1.2mg/day),  compared to  interferon beta-1a, in  patients with relapsing remittingmultiple  sclerosis. Primary  endpoint of  the study  will be brain atrophy. Forfurther  details please see  www.clinicaltrials.gov where the  trial will appearduring this week.About laquinimodLaquinimod  is an oral, investigational, CNS-active immunomodulator with a novelmechanism  of action being developed for the treatment of relapsing-remitting MS(RRMS).  The  global  Phase  III  clinical  development  program evaluating orallaquinimod  in MS includes two pivotal studies, ALLEGRO and BRAVO. A third PhaseIII  laquinimod trial, CONCERTO, is evaluating  two doses of the investigationalproduct  (0.6mg and 1.2mg) in approximately  1,800 patients for up to 24 months.The  primary outcome measure will be time to confirmed disability progression asmeasured by the EDSS.In  addition to the  MS clinical studies,  laquinimod has concluded  Phase II ofdevelopment  for  Crohn's  disease  and  lupus  nephritis.   Further studies areplanned  to determine the effectiveness of  laquinimod in treating patients withHuntington's disease and Alzheimer's disease.About Active BiotechActive  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company withfocus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phaseare   laquinimod,   an   orally   administered   small   molecule   with  uniqueimmunomodulatory properties for the treatment of multiple sclerosis, tasquinimodfor prostate cancer and ANYARA primarily for the treatment of renal cell cancer.In  addition,  laquinimod  has  concluded  Phase  II development for Crohn's andLupus.  The company also has one additional project in clinical development, theorally  administered compound paquinimod  (57-57) for systemic sclerosis. Pleasevisit www.activebiotech.com for more information.For further information:Tomas Leanderson, President & CEOTel: +46 46 19 20 95tomas.leanderson@activebiotech.com  Active Biotech AB (Corp. Reg. No. 556223-9227)  Box 724, SE-220 07 Lund  Tel: +46 46 19 20 00  Fax: +46 46 19 11 00Active Biotech's Safe Harbor Statement in Accordance with the Swedish SecuritiesMarket ActThis  press release  contains certain  forward-looking statements. Such forward-looking  statements  involve  known  and  unknown risks, uncertainties and otherimportant   factors   that  could  cause  the  actual  results,  performance  orachievements  of the company, or industry results, to differ materially from anyfuture  results,  performance  or  achievement  implied  by  the forward-lookingstatements.  The company does not undertake any obligation to update or publiclyrelease   any   revisions  to  forward-looking  statements  to  reflect  events,circumstances or changes in expectations after the date of this press release.Active  Biotech is obligated to publish  the information contained in this pressrelease  in accordance with the Swedish  Securities Market Act. This informationwas provided to the media for publication 08:30 am CET on November 4, 2013.Active Biotech's partner Teva initiates a further clinical trial : http://hugin.info/1002/R/1740139/584195.pdf[HUG#1740139]

If you liked this article you might like

Jim Cramer -- FireEye and Other Cybersecurity Firms Are a Long-Term Play

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Consumer Data in Focus in Coming Week

Consumer Data in Focus in Coming Week

ActivIdentity Soars; Global Payments Slides

ActivIdentity Soars; Global Payments Slides

Stocks Fight Off Fannie, Freddie

Stocks Fight Off Fannie, Freddie